SCHEMBL17491536

SCHEMBL17491536

O=S(=O)(Nc1cc(Cl)cc(-c2cnco2)c1)c1cccc(Cl)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.67
▸ CYP2D6 P10635 1/20 0.67
▸ PSEN1 P49768 1/20 0.67
▸ PSEN2 P49810 1/20 0.67
▸ APH1B Q8WW43 1/20 0.67
▸ NCSTN Q92542 1/20 0.67
▸ APH1A Q96BI3 1/20 0.67
▸ PSENEN Q9NZ42 1/20 0.67
▸ POLB P06746 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ PGR P06401 8/20 0.52
▸ PFKFB3 Q16875 2/20 0.52
▸ PFKFB4 Q16877 1/20 0.52
▸ PTPN2 P17706 3/20 0.48
▸ PTPN1 P18031 3/20 0.48
▸ HSPD1 P10809 1/20 0.48
▸ HSPE1 P61604 1/20 0.48
▸ CCR9 P51686 2/20 0.48
▸ PKM P14618 1/20 0.47
▸ LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17506992 0.87 CYP3A4 (0.56) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL17491543 0.87 CYP3A4 (0.56) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL17491479 0.87 PGR (0.59) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL24913589 0.80 CYP3A4 (1.00) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL17491433 0.77 CYP3A4 (0.47) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL17491381 0.75 NPC1 (0.57) KMT2APKMLMNA
SCHEMBL788034 0.74 PFKFB3 (0.63) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL18394452 0.74 MEN1 (0.64) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL12368209 0.73 KMT2A (1.00) CYP3A4CYP2D6PSEN1PSEN2APH1B
SCHEMBL788132 0.73 PFKFB3 (0.59) CYP3A4CYP2D6PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CYP3A4 315/4885CYP2D6 94/4885PSEN1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback